Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 40

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 40
---
                                |     |                                               | 1,540 |
| Technology platform intangible asset |     |                                               |   181 |
| Other non-current assets**           |     |                                               |     3 |
| Non-current deferred tax liability   |     |                                               |  -292 |
| Other current liabilities***         |     |                                               |   -13 |
| Total identifiable net assets        |     |                                               | 1,551 |
| Goodwill                             |     |                                               |   354 |
| Total consideration                  |     |                                               | 1,905 |

* Includes receivables and other investments

** Includes other investments and right-of-use assets

*** Includes other payables, contract liabilities, lease and other liabilities

The carrying values of other current assets, property and equipment, other non-current assets and other current liabilities were determined to approximate their fair values.

The fair value assigned to acquired IPR&D, which was calculated using the multi-period excess earnings method of the income approach, was based on the present value of expected after-tax cash flows attributable to Rina-S, which was in Phase 1/2 testing. The present value of expected after-tax cash flows obtainable from Rina-S and assigned to IPR&D was determined by estimating the after-tax costs to complete development of Rina-S into a commercially viable product, estimating future revenue and ongoing expenses to produce, support and sell Rina-S, on an after-tax basis, and discounting the resulting net cash flows to present value. The

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 33/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
revenue and costs projections used were reduced based on the probability that compounds at similar stages of development will become commercially viable products. The rate utilized to discount the net cash flows to their present value reflects the risk associated with the future earnings attributable to the intangible asset. Acquired IPR&D will be accounted for as an intangible asset not yet available for use until regulatory approval in a major market is received or development is discontinued.

The fair value of the technology platform intangible asset was calculated using the relief from royalty method of the income approach. This method includes assigning value based on the economic savings from